Foundation Medicine data to have positive effect on reimbursement, says Wedbush After clinical data on gene fusion detection indicated that such detection led to clinical action in about 15% of patients, Wedbush thinks the 15% level will be more than enough for large payors to recognize the importance of deep tumor profiling in some patients. The firm thinks the recent increase in reimbursement rates for BRCA pricing is positive for long-term FoundationOne reimbursement. Wedbush keeps a $50 price target and Outperform rating on Foundation Medicine.
Foundation Medicine appoints Timothy Dec as interim CFO OpGen announced the expansion of its executive management team with the appointments of former Foundation Medicine executive Kevin Krenitsky as president, and Timothy C. Dec as interim CFO. Dec has more than 20 years of public company financial leadership experience in technology and healthcare, and will be charged with ensuring a smooth transition for OpGen from private to public company status and with public company reporting responsibilities.